Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Authors: Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun‐Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, İrfan Çiçin, Sara M. Tolaney, Matthew P. Goetz, Hope S. Rugo, Elżbieta Senkus, Laura Testa, Lucia Del Mastro, Chikako Shimizu, Ran Wei, Ashwin Shahir, Marı́a Jesús Muñoz, Belén San Antonio, Valérie André, Nadia Harbeck, Miguel Martín - The Lancet 2022 cited by 566